 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning Ortho-McNeil Pharmaceutical, Inc.
|
-
Cellzome Receives First Milestone Payment for Alzheimer's Program from Ortho-McNeil Pharmaceutical, Inc.
(03/15/2007)
Cellzome Inc. announced that it has received the first milestone payment for its Gamma Secretase Modulator (GSM) program in connection with the selection of a lead compound by Ortho-McNeil Pharmaceutical, Inc. under its agreement with Cellzome. ...
-
Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications
(11/10/2006)
Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications
After extensive discussions with the regulatory authorities in the U.S. and Europe, Bayer and Ortho-McNeil, Inc. have determined the final design of the phase III study program for the oral anticoagulant rivaroxaban in two chronic indications: ...
-
Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena
(09/05/2005)
Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product
Anika Therapeutics, Inc. announced that it has reached a mutual agreement with OrthoNeutrogena, a division of Ortho-McNeil Pharmaceuticals, for the termination of its development and commercialization contract for Anika's hyaluronic acid based ...
-
Arena Pharmaceuticals Granted Patent for Drug Screening Methods Related to Ortho McNeil, Inc. Collaboration
(08/15/2005)
Arena Pharmaceuticals, Inc. announced that it was granted patent number 1133559, entitled "HUMAN ORPHAN G PROTEIN-COUPLED RECEPTOR RUP3," by the European Patent Office. The patent relates to certain drug screening methods utilizing the 19AJ ...
-
7TM Pharma Enters Discovery Collaboration with Ortho-McNeil To Develop Novel Compounds for Asthma and Allergic Diseases
(06/13/2005)
7TM Pharma A/S announced that it has entered into an exclusive worldwide license agreement and research collaboration with Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, to further develop 7TM Pharma's program on novel oral ...
-
Addex Pharmaceuticals enters into Collaboration with Ortho-McNeil Pharmaceutical to Develop Novel Treatments
(01/18/2005)
Addex Pharmaceuticals announced that it has entered an exclusive worldwide research collaboration and licence agreement with Ortho-McNeil Pharmaceutical, Inc. to discover, develop and commercialize novel compounds modulating allosterically G-Protein ...
|
|
|
|
|
Top